Serial No.: 10/632,581 Filed : July 31, 2003

Page 4

Amendment to the claims:

The following listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of claims:

- 1. (currently amended) An <u>isolated</u> adult multipotent human stem cell [[,]] characterized in that it has comprising:
 - i) significant telomerase activity of at least 20% to 50% of the telomerase activity of the HEK293T transformed cell line,
 - ii) an HLA Class I negative phenotype,
 - iii) a normal karyotype,
 - iv) a capacity to become quiescent, and
 - v) a capacity for self-renewal preserved for at least 130 population doublings.
- 2. (currently amended) The stem cell according to claim 1, characterized in that it wherein the stem cell has a selfrenewal capacity preserved for at least 200 population doublings.
- 3. (currently amended) The stem cell according to claim 1 or claim 2, characterized in that it wherein the stem cell can be isolated from human adipose tissue.
- 4. (currently amended) The stem cell according to any one of the preceding claims of claim 3, characterized in that it wherein the stem cell can differentiate into a cell of

Serial No.: 10/632,581 Filed : July 31, 2003

Page 5

endodermal, ectodermal or mesodermal origin.

- 5. (currently amended) The stem cell according to of claim 4, characterized in that it wherein the stem cell is capable of differentiating into an adipocyte, osteoblast, myocyte, chondrocyte or endothelial cell.
- 6. (currently amended) The stem cell according to any one of the preceding claims of claim 5, characterized in that it wherein the stem cell has a telomerase activity corresponding to at least 20% of the telomerase activity of a reference cell line.
- 7. (currently amended) The stem cell according to any one of the preceding claims of claim 6, characterized in that it wherein the stem cell expresses the transcription factor Oct-4 and/or Rex-1.
- 8. (cancelled)
- 9. (currently amended) A cell population comprising a plurality of cells according to as in any one of claims 1, [[or]] 51 [[to 54]] and 53, characterized in that it wherein the cell population is free of adipocytes, fibroblasts, preadipocytes, endothelial cells, pericytes, mastocytes, and smooth muscle cells.
- 10. (currently amended) <u>The</u> cell population according to of claim 9, characterized in that it wherein the cell

Serial No.: 10/632,581 Filed : July 31, 2003

Page 6

population is clonal.

- 11. (currently amended) The cell population according to any one of claims 9 or elaim 10, characterized in that it wherein the cell population becomes quiescent after about 60 population doublings.
- 12. (currently amended) The cell population according to of claim 11, characterized in that it wherein the cell population is capable of proliferating in the presence of growth factors such as basic fibroblast growth factor (bFGF), PDGF, EGF, NGF, SCF.
- 13. 24. (cancelled)
- 25. (currently amended) Stem cells obtainable by carrying out the method according to any one of claims claim 13 [[to 24]].
- 26. (currently amended) Stem cells according to any one of claims 1 [[to 12]] or 25, for use in therapy.
- 27. (currently amended) Stem cells according to of claim 26, characterized in that wherein the therapy comprises transplantation of cells into an individual followed by cell differentiation and tissue regeneration in vivo.
- 28. (currently amended) Stem cells according to of claim 26, eharacterized in that wherein transplantation is allogenic.

Serial No.: 10/632,581 Filed : July 31, 2003

Page 7

- 29. 47. (cancelled)
- 48. (currently amended) A pharmaceutical composition comprising a plurality of cells according to any one of claims 1 [[to 13]] or 25, in association with and a physiologically acceptable excipient.
- 49. (currently amended) An <u>isolated</u> adult multipotent human cell, termed a "CS" cell, characterized in that wherein the cell:
 - i) [[it]] has an HLA Class I negative phenotype,
 - ii) [[it]] has a normal karyotype,
 - iii) [[it]] has a self-renewal capacity that is preserved for about 40 to 60 population doublings,
 - iv) [[it]] is not capable of becoming quiescent, and
 - v) [[its]] <u>has a proliferation rate which</u> is not affected by LIF.
- 50. (currently amended) [[A]] An isolated multipotent human cell population termed a "CS" population comprising a plurality of cells according to claim 49.
- 51. (currently amended) <u>The</u> stem cell according to any one of <u>claims</u> <u>claim</u> 1 [[to 8]], <u>characterized in that it wherein</u> <u>the cell</u> has the following phenotype:

HLA class I negative;

HLA class II negative;

CD3 negative;

Serial No.: 10/632,581 Filed : July 31, 2003

Page 8

CD13 positive;

- 52. (currently amended) The stem cell according to any one of claims 1 [[to 8]] or 51, characterized in that it wherein the cell has a CD13 positive phenotype in the presence of 10% foetal calf serum.
- 53. (currently amended) An <u>isolated</u> adult multipotent human stem cell, characterized in that after reaching quiescence, it stably exhibits the following phenotype in vitro:

HLA class I negative,

HLA class II negative,

CD3 negative,

CD13 positive,

LIF-R negative,

Oct-4 positive,

Rex-1 positive,

ABCG2 positive,

and in that it has a normal karyotype and significant telomerase activity of at least 20% to 50% of the telomerase activity of the HEK293T transformed cell line.

54. (currently amended) The cell according to of claim 53, characterized in that it wherein the cell has immunoprivileged behavior in vivo and a capacity to migrate in the undifferentiated state.